Company: CERO
Filing Date: 2025-08-11
Form Type: S-3
Source: 0001213900-25-073849
Chunk: 32

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-11
Form: S-3
Chunk 32
---
 incurred by such person in any such capacity, or arising out
of his or her status as such, whether or not the corporation would have the power to indemnify the person against such liability under
Section 145 of the DGCL.

Section 102(b)(7) of the
DGCL provides that a corporation’s certificate of incorporation may contain a provision eliminating or limiting the personal liability
of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director; provided that such
provision shall not eliminate or limit the liability of a director (i) for any breach of the director’s duty of loyalty to the corporation
or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law,
(iii) under Section 174 of the DGCL or (iv) for any transaction from which the director derived an improper personal benefit.

Additionally, our Charter
and Bylaws limit the liability of our (i) directors and (ii) officers, which includes each individual who has been duly appointed as an
officer of CERo and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service of
process to our registered agent as contemplated by Section 3114(b) of Title 10 of the DGCL, in each case, to the fullest extent permitted
by the DGCL, and also provides that we indemnify our directors and officers to the fullest extent permitted by the DGCL.

In connection with the Closing,
we entered into indemnification agreements with each of our directors and executive officers. These agreements provide that we indemnify
each of our directors and officers to the fullest extent permitted by law and our Charter and Bylaws, and provides for advancement of
expenses incurred as a result of any proceeding against them as to which they could be indemnified.

We also maintain a general
liability insurance policy, which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions
in their capacities as directors or officers.

<div align='center'>II-2</div>

Item 16. Exhibits and Financial Statements Schedules.

(a) Exhibits.

| Exhibit 
 Number  
 2.1     
 2.2     |     | Description                                                                                                                                                                                                                                                                                                                                                                       
 Business Combination Agreement, dated as of June 4, 2023, by and among Phoenix Biotech Acquisition Corp., PBCE